Considerations for Construct and Affinity Design Goals

  • Mohammad A. TabriziEmail author
  • Scott L. KlakampEmail author


Application of an integrated approach for inclusion of pharmacology principles in drug development is a foundational step for effective modality design and selection of antibody-based therapeutics. Clarity on patient-related variables, manufacturing considerations, underlying biology and pathophysiology, as well as integration of key translational variables can accelerate drug development processes, ultimately benefiting patients in need of such therapies. Establishing design goals with respect to antibody affinity is a necessary step for achieving this goal and should be incorporated into the development strategies from the earliest stages of the discovery process for biologic modalities. Evaluation of affinity design goals is a complex process contingent on many critical variables. Knowledge of the target antigen biology and its role in the pathogenesis of disease is of high importance in establishing affinity design goals. Selection of the adequate affinity for a functional biologic construct should allow achievement of the maximum therapeutic benefit at a dose associated with a manageable cost of goods. This chapter will further expand on the topics discussed previously (Development of antibody-based therapeutics: translational considerations, Springer, New York, 2012).


  1. Bodmer J-L, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27(1):19–26.CrossRefGoogle Scholar
  2. Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol. 2013;2013:1–25. Article ID 371854: Hindawi Publishing Corporation.CrossRefGoogle Scholar
  3. Deanne M, Compaan DM, Hymowitz SG. The crystal structure of the costimulatory OX40-OX40L complex. Structure. 2006;14:1321–30.CrossRefGoogle Scholar
  4. Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013;185(4):297–305.CrossRefPubMedGoogle Scholar
  5. Huskens J. Multivalent interactions at interfaces. Curr Opin Chem Biol. 2006;10:537–43.CrossRefGoogle Scholar
  6. Kenakin T. Stimulus-response mechanisms. In: Weissman G, editor. Pharmacologic analysis of drug–receptor interaction. New York: Raven Press; 1993. p. 39–68.Google Scholar
  7. Klotz IM. Ligand-receptor energetics: a guide for the perplexed. New York: Wiley; 1997. 192p.Google Scholar
  8. Klotz IM, Hunston DL. Protein affinities for small molecules: conceptions and misconceptions. Arch Biochem Biophys. 1979;193:314–28.CrossRefGoogle Scholar
  9. Krishnamurthy VM, Estroff LA, Whitesides GM. Multivalency in ligand design (Chapter 2). In: Jahnke W, Erlanson DA, editors. Fragment based approaches in drug discovery. Weinheim, Germany: Wiley-VCH; 2006.Google Scholar
  10. Lahiri J, Isaacs L, Grybowski B, Carbeck JD, Whitesides GM. Bispecific binding of carbonic anhydrase to mixed SAMs presenting benzenesulfonamide ligands: a model system for studying lateral steric effects. Langmuir. 1999;15:7186–98.CrossRefGoogle Scholar
  11. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001;108:971–9.CrossRefPubMedGoogle Scholar
  12. Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157–69.CrossRefGoogle Scholar
  13. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.CrossRefGoogle Scholar
  14. Lundquist JJ, Toone EJ. The cluster glycoside effect. Chem Rev. 2002;102:555–78.CrossRefGoogle Scholar
  15. Mack ET, Snyder PW, Perez-Castillejos R, Whitesides GM. Using covalent dimers of human carbonic anhydrase II to model bivalency in immunoglobulins. J Am Chem Soc. 2011a;133:11701–15.CrossRefPubMedGoogle Scholar
  16. Mack ET, Cummings L, Perez-Castillejos R. Mathematical model for determining the binding constants between immunoglobulins, bivalent ligands, and monovalent ligands. Anal Bioanal Chem. 2011b;399:1641–52.CrossRefGoogle Scholar
  17. Mack ET, Snyder PW, Perez-Castillejos R, Bilgicer B, Moustakas DT, Butte MJ, Whitesides GM. Dependence of avidity on linker length for a bivalent ligand-bivalent receptor model system. J Am Chem Soc. 2012a;134:333–45.CrossRefGoogle Scholar
  18. Mack ET, Bracher PJ, Perez-Castillejos R. Thermodynamic analysis to assist in the design of recombinant antibodies. Crit Rev Immunol. 2012b;32:503–27.CrossRefGoogle Scholar
  19. Tabrizi M, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009a;14(5–6):298–305.CrossRefGoogle Scholar
  20. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2009b;12:33–43.CrossRefPubMedGoogle Scholar
  21. Tabrizi M, Funelas C, Suria H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J. 2010;12(4):592–601.CrossRefPubMedGoogle Scholar
  22. Tabrizi M, Bornstein GG, Klakamp SL. Development of antibody-based therapeutics: translational considerations. New York: Springer; 2012.CrossRefGoogle Scholar
  23. Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22:1727–41.CrossRefPubMedGoogle Scholar
  24. Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183:1851–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Merck & Co., Inc.Palo AltoUSA
  2. 2.SKD Consulting LLCBroomfieldUSA

Personalised recommendations